Curia New York, Inc. — FDA Warning Letter, 2026-09-18: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
TL;DR
Here's the summary: FDA Warning Letter cgmp: Curia New York, Inc. — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated (2026-09-18). Entities: Curia New York, Inc..
Argus analysis
# FDA Warning Letter Analysis: Curia New York, Inc.
**Company and Findings**
Curia New York, Inc., a drug manufacturing facility in Rensselaer, New York (FEI 1310298), received a warning letter from FDA's Center for Drug Evaluation and Research on September 18, 2026, following a January–February 2026 inspection. The FDA documented significant deviations from Current Good Manufacturing Practice (CGMP) in the production of active pharmaceutical ingredients (APIs). The agency determined that the company's APIs are adulterated because manufacturing methods, facilities, and controls do not conform to CGMP standards under the Federal Food, Drug, and Cosmetic Act.
**Regulatory Citations and Meaning**
The warning letter cites violations under 21 CFR sections governing laboratory controls, data integrity, and quality oversight. Specifically, Curia failed to maintain complete laboratory control records for API testing, with thousands of undocumented or inadequately justified injections performed on chromatography equipment (HPLC and UPLC) over 30 months. Additionally, the quality unit did not exercise adequate oversight: original analytical records (pH readings, balance printouts, signed checklists) were discarded in shred bins without proper traceability, and laboratory personnel reviewed photocopies of notebooks rather than original data before sign-off. These deviations reflect failures in data integrity and record retention—core CGMP requirements ensuring drug safety and efficacy.
**Next Steps and Industry Monitoring**
Curia has a statutory obligation to promptly correct these deviations. The company must submit a comprehensive independent investigation of all trial injections and a facility-wide data-integrity assessment covering all computerized CGMP systems. Industry observers should monitor whether Curia issues a public response, initiates recalls of distributed APIs, or receives follow-up inspection findings. Failure to adequately address violations may trigger seizure or injunction proceedings.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Curia New York, Inc. MARCS-CMS 728790 — September 18, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Reference #: 320-26-127 Product: Drugs Recipient: Recipient Name Philip Macnabb Recipient Title CEO Curia New York, Inc. 223 South West Street Raleigh , NC 27603 United States (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States September 18, 2026 WARNING LETTER Reference number: 320-26-127 To Mr. Philip Macnabb: This warning letter advises you of significant deviations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the deviations described herein without delay, including ensuring that appropriate resources are allocated to fully address the deviations and prevent their recurrence. This is not intended to be an all-inclusive list of the deviations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address deviations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Deviations were observed and documented during an inspection of your drug manufacturing facility, Curia New York, Inc., FDA Establishment Identifier (FEI) 1310298 at 33 Riverside Avenue, Rensselaer, New York, from January 28 to February 5, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your February 27, 2026, response to our Form FDA 483 in detail, and we also acknowledge receipt of your subsequent correspondence. Violations of the Federal Food, Drug, and Cosmetic Act The following are deviations identified during our inspection and review. As a reminder, this is not an all-inclusive list of deviations at your establishment. 1. Failure to have laboratory control records that include complete data derived from all laboratory tests conducted to ensure your API and intermediates comply with established specifications and standards. Not all electronic test results are included in your review to determine conformance of your API products. Your laboratory analysts routinely conducted unexplained injections in high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) without adequate documentation or supervision to ens…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Curia New York, Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Curia New York, Inc. as of 2026-09-29. Argus ingests new FDA enforcement records daily.
- What FDA violations was Curia New York, Inc. cited for?
- The FDA Warning Letter to Curia New York, Inc. (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Curia New York, Inc.?
- FDA issued the letter (MARCS-CMS 728790) on 2026-09-18 and posted it publicly on fda.gov on 2026-09-29.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Curia New York, Inc. — FDA Warning Letter, 2026-09-18: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-curia-new-york-inc-2026-09-18-cgmp
"Curia New York, Inc. — FDA Warning Letter, 2026-09-18: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-curia-new-york-inc-2026-09-18-cgmp.
Argus HQ Research. "Curia New York, Inc. — FDA Warning Letter, 2026-09-18: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated." Digital Empire Holdings LLC. Accessed September 30, 2026. https://argushq.ai/fda/warning-letter/fda-wl-curia-new-york-inc-2026-09-18-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_curia_new_york_inc_2026_09_18_cgmp_2026,
title = {Curia New York, Inc. — FDA Warning Letter, 2026-09-18: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-curia-new-york-inc-2026-09-18-cgmp},
note = {Accessed: September 30, 2026}
}